Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Association of female sex and positive rheumatoid factor with low serum infliximab and anti-drug antibodies, related to treatment failure in early rheumatoid arthritis: results from the SWEFOT trial population.

Hambardzumyan K, Hermanrud C, Marits P, Vivar N, Ernestam S, Wallman JK, van Vollenhoven RF, Fogdell-Hahn A, Saevarsdottir S; SWEFOT study group.

Scand J Rheumatol. 2019 Jun 27:1-5. doi: 10.1080/03009742.2019.1602670. [Epub ahead of print]

PMID:
31244356
2.

Severe combined immunodeficiency (SCID) presenting in childhood, with agammaglobulinemia, associated with novel compound heterozygous mutations in DCLRE1C.

Sundin M, Marits P, Ramme K, Kolios AGA, Nilsson J.

Clin Immunol. 2019 Mar;200:16-18. doi: 10.1016/j.clim.2018.12.019. Epub 2019 Jan 7.

PMID:
30630113
3.

CCR2 upregulated on peripheral T cells in osteoarthritis but not in bone marrow.

Arkestål K, Mints M, Enocson A, Linton L, Marits P, Glise H, Andersson J, Winqvist O.

Scand J Immunol. 2018 Dec;88(6):e12722. doi: 10.1111/sji.12722. Epub 2018 Oct 28.

PMID:
30403025
4.

Eleven percent intact PGM3 in a severely immunodeficient patient with a novel splice-site mutation, a case report.

Lundin KE, Wang Q, Hamasy A, Marits P, Uzunel M, Wirta V, Wikström AC, Fasth A, Ekwall O, Smith CIE.

BMC Pediatr. 2018 Aug 29;18(1):285. doi: 10.1186/s12887-018-1258-9.

5.

Increased CD4+ T cell lineage commitment determined by CpG methylation correlates with better prognosis in urinary bladder cancer patients.

Ahlén Bergman E, Hartana CA, Johansson M, Linton LB, Berglund S, Hyllienmark M, Lundgren C, Holmström B, Palmqvist K, Hansson J, Alamdari F, Huge Y, Aljabery F, Riklund K, Winerdal ME, Krantz D, Zirakzadeh AA, Marits P, Sjöholm LK, Sherif A, Winqvist O.

Clin Epigenetics. 2018 Aug 3;10(1):102. doi: 10.1186/s13148-018-0536-6.

6.

"Immune" Thrombocytopenia as Key Feature of a Novel ADA2 Deficiency Variant: Implication on Differential Diagnostics of ITP in Children.

Sundin M, Marits P, Nierkens S, Kolios AGA, Nilsson J.

J Pediatr Hematol Oncol. 2019 Mar;41(2):155-157. doi: 10.1097/MPH.0000000000001132.

PMID:
29620681
7.

Urinary Bladder Cancer Tregs Suppress MMP2 and Potentially Regulate Invasiveness.

Winerdal ME, Krantz D, Hartana CA, Zirakzadeh AA, Linton L, Bergman EA, Rosenblatt R, Vasko J, Alamdari F, Hansson J, Holmström B, Johansson M, Winerdal M, Marits P, Sherif A, Winqvist O.

Cancer Immunol Res. 2018 May;6(5):528-538. doi: 10.1158/2326-6066.CIR-17-0466. Epub 2018 Mar 27.

8.

Late presenting atypical severe combined immunodeficiency (SCID) associated with a novel missense mutation in DCLRE1C.

Sundin M, Uhlin M, Gaballa A, Ramme K, Kolios AG, Marits P, Nilsson J.

Pediatr Allergy Immunol. 2018 Feb;29(1):108-111. doi: 10.1111/pai.12812. Epub 2017 Dec 12. No abstract available.

PMID:
28981982
9.

Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on  Maintenance Treatment.

Rolandsdotter H, Marits P, Sundin U, Wikström AC, Fagerberg UL, Finkel Y, Eberhardson M.

Int J Mol Sci. 2017 Mar 7;18(3). pii: E575. doi: 10.3390/ijms18030575.

10.

Doxorubicin enhances the capacity of B cells to activate T cells in urothelial urinary bladder cancer.

Zirakzadeh AA, Kinn J, Krantz D, Rosenblatt R, Winerdal ME, Hu J, Hartana CA, Lundgren C, Bergman EA, Johansson M, Holmström B, Hansson J, Sidikii A, Vasko J, Marits P, Sherif A, Winqvist O.

Clin Immunol. 2017 Mar;176:63-70. doi: 10.1016/j.clim.2016.12.003. Epub 2016 Dec 24.

PMID:
28025135
11.

Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report.

Rosenblatt R, Johansson M, Alamdari F, Sidiki A, Holmström B, Hansson J, Vasko J, Marits P, Gabrielsson S, Riklund K, Winqvist O, Sherif A.

World J Urol. 2017 Jun;35(6):921-927. doi: 10.1007/s00345-016-1952-x. Epub 2016 Oct 13.

12.

Pilot study of adoptive immunotherapy with sentinel node-derived T cells in muscle-invasive urinary bladder cancer.

Sherif A, Hasan MN, Radecka E, Rodriguez AL, Shabo S, Karlsson M, Schumacher MC, Marits P, Winqvist O.

Scand J Urol. 2015 Dec;49(6):453-462. doi: 10.3109/21681805.2015.1059880. Epub 2015 Jul 4.

PMID:
26144252
13.

Evaluation of T and B lymphocyte function in clinical practice using a flow cytometry based proliferation assay.

Marits P, Wikström AC, Popadic D, Winqvist O, Thunberg S.

Clin Immunol. 2014 Aug;153(2):332-42. doi: 10.1016/j.clim.2014.05.010. Epub 2014 Jun 6.

PMID:
24909732
14.

Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment.

Marits P, Landucci L, Sundin U, Davidsdottir L, Nilsson J, Befrits R, Wikström AC, Eberhardson M.

J Crohns Colitis. 2014 Aug;8(8):881-9. doi: 10.1016/j.crohns.2014.01.009. Epub 2014 Jan 31.

PMID:
24486178
15.

The many flavors of tumor-associated B cells.

Marits P, Zirakzadeh AA, Sherif A, Winqvist O.

Oncoimmunology. 2013 Aug 1;2(8):e25237. Epub 2013 Jun 10.

16.

Response to comment on "multiplex B cell characterization in blood, lymph nodes, and tumors from patients with malignancies".

Marits P, Zirakzadeh AA, Sherif A, Winqvist O.

J Immunol. 2013 Nov 1;191(9):4471-2. doi: 10.4049/jimmunol.1390053. No abstract available.

17.

Treatment of inflammatory bowel disease by chemokine receptor-targeted leukapheresis.

Eberhardson M, Marits P, Jones M, Jones P, Karlen P, Karlsson M, Cotton G, Woznica K, Maltman B, Glise H, Winqvist O.

Clin Immunol. 2013 Oct;149(1):73-82. doi: 10.1016/j.clim.2013.05.021. Epub 2013 Jun 13.

PMID:
23892544
18.

Multiplex B cell characterization in blood, lymph nodes, and tumors from patients with malignancies.

Zirakzadeh AA, Marits P, Sherif A, Winqvist O.

J Immunol. 2013 Jun 1;190(11):5847-55. doi: 10.4049/jimmunol.1203279. Epub 2013 Apr 29.

19.

Predictive immunomonitoring -- the COST ENTIRE initiative.

Popadic D, Anegon I, Baeten D, Eibel H, Giese T, Marits P, Martinez-Caceres E, Mascart F, Nestle F, Pujol-Borrell R, Savic E, Scheibenbogen C, Seliger B, Thunberg S, Turina M, Villanova F, Winqvist O, Wikström AC.

Clin Immunol. 2013 Apr;147(1):23-26. doi: 10.1016/j.clim.2013.01.013. Epub 2013 Feb 8. No abstract available.

PMID:
23454893
20.

FOXP3 and survival in urinary bladder cancer.

Winerdal ME, Marits P, Winerdal M, Hasan M, Rosenblatt R, Tolf A, Selling K, Sherif A, Winqvist O.

BJU Int. 2011 Nov;108(10):1672-8. doi: 10.1111/j.1464-410X.2010.10020.x. Epub 2011 Jan 18.

21.

Profiling of CD4+ T cells with epigenetic immune lineage analysis.

Janson PC, Linton LB, Bergman EA, Marits P, Eberhardson M, Piehl F, Malmström V, Winqvist O.

J Immunol. 2011 Jan 1;186(1):92-102. doi: 10.4049/jimmunol.1000960. Epub 2010 Dec 3.

22.

Pilot study of sentinel-node-based adoptive immunotherapy in advanced colorectal cancer.

Karlsson M, Marits P, Dahl K, Dagöö T, Enerbäck S, Thörn M, Winqvist O.

Ann Surg Oncol. 2010 Jul;17(7):1747-57. doi: 10.1245/s10434-010-0920-8. Epub 2010 Jan 30.

23.

Feasibility of T-cell-based adoptive immunotherapy in the first 12 patients with advanced urothelial urinary bladder cancer. Preliminary data on a new immunologic treatment based on the sentinel node concept.

Sherif A, Hasan MN, Marits P, Karlsson M, Winqvist O, Thörn M.

Eur Urol. 2010 Jul;58(1):105-11. doi: 10.1016/j.eururo.2009.09.026. Epub 2009 Sep 11.

PMID:
19766386
24.
25.

Metinel node--the first lymph node draining a metastasis--contains tumor-reactive lymphocytes.

Dahl K, Karlsson M, Marits P, Hoffstedt A, Winqvist O, Thörn M.

Ann Surg Oncol. 2008 May;15(5):1454-63. doi: 10.1245/s10434-007-9788-7. Epub 2008 Feb 26.

26.

FOXP3 promoter demethylation reveals the committed Treg population in humans.

Janson PC, Winerdal ME, Marits P, Thörn M, Ohlsson R, Winqvist O.

PLoS One. 2008 Feb 20;3(2):e1612. doi: 10.1371/journal.pone.0001612.

27.

Sentinel node lymphocytes: tumour reactive lymphocytes identified intraoperatively for the use in immunotherapy of colon cancer.

Marits P, Karlsson M, Dahl K, Larsson P, Wanders A, Thörn M, Winqvist O.

Br J Cancer. 2006 May 22;94(10):1478-84.

28.

Increased antigen presenting cell-mediated T cell activation in mice and patients without the autoimmune regulator.

Ramsey C, Hässler S, Marits P, Kämpe O, Surh CD, Peltonen L, Winqvist O.

Eur J Immunol. 2006 Feb;36(2):305-17.

29.

Detection of immune responses against urinary bladder cancer in sentinel lymph nodes.

Marits P, Karlsson M, Sherif A, Garske U, Thörn M, Winqvist O.

Eur Urol. 2006 Jan;49(1):59-70. Epub 2005 Nov 14.

PMID:
16321468
30.

Analysis of T-cell receptor V beta gene repertoires after immune stimulation and in malignancy by use of padlock probes and microarrays.

Banér J, Marits P, Nilsson M, Winqvist O, Landegren U.

Clin Chem. 2005 Apr;51(4):768-75. Epub 2005 Feb 3.

Supplemental Content

Loading ...
Support Center